The Food and Drug Administration announced Tuesday that it will convene a meeting of its Veterinary Medicine Advisory Committee on Sept. 19 and Sept. 20 to review scientific data and make a recommendation about whether a genetically engineered salmon is fit for the dinner plate.
In addition, the FDA will hold a public hearing on Sept. 21 on whether the salmon should be labeled as genetically modified. That’s considered a key issue in whether the public accepts the fish.
The salmon, developed by AquaBounty Technologies Inc. of Waltham, Mass., grows to market weight in half the usual time.
The firm contends it can avoid the pollution, disease and other problems associated with saltwater fish farms by raising the salmon at inland facilities.
To read the rest of the story, please go to: Los Angeles Times.
